Polimorfismos da CYP2D6 na terapia medicamentosa no transtorno do espectroautista (TEA) em crianças e adolescentes
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: O transtorno do espectro autista (TEA) compromete o desenvolvimento neuropsicomotor, dificultando a cognição, linguagem e interação social. É de etiologia genética e atualmente, o tratamento de sintomas comportamentais graves relacionados a ele é realizado com antipsicóticos, principalmente com a risperidona e o aripiprazol.
Objetivo: Descrever no TEA a influência dos polimorfismos genéticos da enzima CYP2D6 no tratamento com risperidona e o aripiprazol.
Método: Busca eletrônica de janeiro/2023 a dezembro/2023 nas principais bases de dados científicas, utilizando combinações de descritores MeSH/DeCS e termos livres relacionados ao TEA (“Transtorno do Espectro Autista”, “Autismo”), aos fármacos (“risperidona”, “aripiprazol”), às manifestações clínicas (“comportamento disruptivo”, “irritabilidade”, “estereotipias”) e farmacogenômica (“alelos CYP2D6*3 e CYP2D6*4, “metabolizadores”).
Resultado: Foram incluídos 72 artigos nos idiomas português, inglês e espanhol, publicados entre 2010 e 2024.
Conclusão: TEA se manifesta de forma diversificada, e o entendimento de suas características clínicas, tratamento medicamento e conhecimento da farmacogenética dos medicamentos é de grande importância para controle adequado da doença e melhora da qualidade de vida.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
Bialer M, Voltolini R. Autismo: história de um quadro e o quadro de uma história. Psicol Estud. 2022;27:e45865. https://doi.org/10.4025/psicolestud.v27i0.45865
First MB, American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. 5th ed. Washington: American Psychiatric Publishing; 2022.
Masi A, DeMayo MM, Glozier N, Guastella AJ. An overview of autism spectrum disorder, heterogeneity and treatment options. Neurosci Bull. 2017;33(2):183-93. https://doi.org/10.1007/s12264-017-0100-y
Mano-Sousa BJ, Pedrosa AM, Alves BC, Galduróz JCF, Belo VS, Chaves VE, et al. Effects of risperidone in autistic children and young adults: a systematic review and meta-analysis. Curr Neuropharmacol. 2021;19(4):538-52. https://doi.org/10.2174/1570159x18666200529151741
Vanwong N, Ngamsamut N, Medhasi S, Puangpetch A, Chamnanphon M, Tan-Kam T, et al. Impact of CYP2D6 polymorphism on steady-state plasma levels of risperidone and 9-hydroxyrisperidone in Thai children and adolescents with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2017;27(2):185-91. https://doi.org/10.1089/cap.2014.0171
Munro AW, Lindsay JG. Bacterial cytochromes P-450. Mol Microbiol. 1996;20(6):1115-25. https://doi.org/10.1111/j.1365-2958.1996.tb02632.x
Raposo ACB. Variação genética do gene CYP2D6 na analgesia do parto: abordagem farmacogenómica [dissertação]. Coimbra: Universidade de Coimbra; 2011. Available from: https://estudogeral.uc.pt/handle/10316/18449
Gomes PTM, Lima LHL, Bueno MKG, Araújo LA, Souza NM. Autism in Brazil: a systematic review of family challenges and coping strategies. J Pediatr (Rio J). 2015;91(2):111-21. https://doi.org/10.1016/j.jped.2014.08.009
Sousa L, De Meireles H, Pessoa J. A inclusão do aluno autista em uma escola da rede estadual de ensino de João Pessoa [trabalho de conclusão de curso]. João Pessoa: Universidade Federal da Paraíba; 2020. Available from: https://repositorio.ufpb.br/jspui/handle/123456789/17947
Fernandes CS, Tomazelli J, Girianelli VR. Diagnóstico de autismo no século XXI: evolução dos domínios nas categorizações nosológicas. Psicol USP. 2020;31:e200027. Available from: https://doi.org/10.1590/0103-6564e200027
Centers for Disease Control and Prevention. Autism and Developmental Disabilities Monitoring (ADDM) Network. 2024. Available from: https://www.cdc.gov/autism/addm-network/index.html
Loomes R, Hull L, Mandy WPL. What is the male-to-female ratio in autism spectrum disorder? A systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry. 2017;56(6):466-74. https://doi.org/10.1016/j.jaac.2017.03.013
James LW, Pizur-Barnekow KA, Schefkind S. Online survey examining practitioners’ perceived preparedness in the early identification of autism. Am J Occup Ther. 2014;68(1):e13-20. https://doi.org/10.5014/ajot.2014.009027
Organização das Nações Unidas. OMS afirma que autismo afeta uma em cada 160 crianças no mundo. ONU News. 2017. Available from: https://news.un.org/pt/audio/2017/04/1201661
Mottron L, Bzdok D. Autism spectrum heterogeneity: fact or artifact? Mol Psychiatry. 2020;25(12):3178-85. https://doi.org/10.1038/s41380-020-0748-y
King MD, Fountain C, Dakhlallah D, Bearman PS. Estimated autism risk and older reproductive age. Am J Public Health. 2009;99(9):1673-9. https://doi.org/10.2105/ajph.2008.149021
Schieve LA, Rice C, Devine O, Maenner MJ, Lee LC, Fitzgerald R, et al. Have secular changes in perinatal risk factors contributed to the recent autism prevalence increase? Development and application of a mathematical assessment model. Ann Epidemiol. 2011;21(12):930. https://doi.org/10.1016/j.annepidem.2011.08.009
Parner ET, Thorsen P, Dixon G, De Klerk N, Leonard H, Nassar N, et al. A comparison of autism prevalence trends in Denmark and Western Australia. J Autism Dev Disord. 2011;41(12):1601-8. https://doi.org/10.1007/s10803-011-1186-0
King M, Bearman P. Diagnostic change and the increased prevalence of autism. Int J Epidemiol. 2009;38(5):1224-34. https://doi.org/10.1093/ije/dyp261
Evêncio KMM, Cristina H, Menezes S, Fernandes P. Transtorno do espectro do autismo: considerações sobre o diagnóstico. ID Online Rev Psicol. 2019;13(47):234-51. https://doi.org/10.14295/idonline.v13i47.1983
Lederman VRG, Goulart AL, Santos AMN, Schwartzman JS. Rastreamento de sinais sugestivos de TEA em prematuros com muito baixo peso ao nascer. Psicol Teor Prat. 2018;20(3):86-99. https://doi.org/10.5935/1980-6906/psicologia.v20n3p86-99
Gupta AR, State MW. Autismo: genética. Braz J Psychiatry. 2006;28(Suppl 1):s29-38. https://doi.org/10.1590/S1516-44462006000500005
Ivanov HY, Stoyanova VK, Popov NT, Vachev TI. Autism spectrum disorder – a complex genetic disorder. Folia Med (Plovdiv). 2015;57(1):19-28. https://doi.org/10.1515/folmed-2015-0015
Maria S, Brito MC. Transtornos do espectro do autismo e educação inclusiva: análise de atitudes sociais de professores e alunos frente à inclusão. Rev Educ Espec. 2017;30(59):657-68. https://doi.org/10.5902/1984686X28086
Eapen V. Genetic basis of autism: is there a way forward? Curr Opin Psychiatry. 2011;24(3):226-36. https://doi.org/10.1097/yco.0b013e328345927e
Manoli DS, State MW. Autism spectrum disorder genetics and the search for pathological mechanisms. Am J Psychiatry. 2021;178(1):30-8. https://doi.org/10.1176/appi.ajp.2020.20111608
Trost B, Engchuan W, Nguyen CM, Thiruvahindrapuram B, Dolzhenko E, Backstrom I, et al. Genome-wide detection of tandem DNA repeats that are expanded in autism. Nature. 2020;586(7827):80-6. https://doi.org/10.1038/s41586-020-2579-z
Doan RN, Lim ET, De Rubeis D, Betancur C, Cutler DJ, Chiocchetti AG, et al. Recessive gene disruptions in autism spectrum disorder. Nat Genet. 2019;51(7):1092-8. https://doi.org/10.1038/s41588-019-0433-8
Pinto D, Delaby E, Merico D, Barbosa M, Merikangas A, Klei L, et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet. 2014;94(5):677-94. https://doi.org/10.1016/j.ajhg.2014.03.018
Yuen RKC, Merico D, Bookman M, Howe JL, Thiruvahindrapuram B, Patel RV, et al. Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder. Nat Neurosci. 2017;20(4):602-11. https://doi.org/10.1038/nn.4524
Miles JH. Autism spectrum disorders – a genetics review. Genet Med. 2011;13(4):278-94. https://doi.org/10.1097/gim.0b013e3181ff67ba
Genovese A, Butler MG. Clinical assessment, genetics, and treatment approaches in autism spectrum disorder (ASD). Int J Mol Sci. 2020;21(13):1-18. https://doi.org/10.3390/ijms21134726
Ho KS, Wassman ER, Baxter AL, Hensel CH, Martin MM, Prasad A, et al. Chromosomal microarray analysis of consecutive individuals with autism spectrum disorders using an ultra-high resolution chromosomal microarray optimized for neurodevelopmental disorders. Int J Mol Sci. 2016;17(12):1-13. https://doi.org/10.3390/ijms17122070
Woodbury-Smith M, Paterson AD, O’Connor I, Zarrei M, Yuen RKC, Howe JL, et al. A genome-wide linkage study of autism spectrum disorder and the broad autism phenotype in extended pedigrees. J Neurodev Disord. 2018;10(1):20. https://doi.org/10.1186/s11689-018-9238-9
Zhou X, Feliciano P, Shu C, Wang T, Astrovskaya I, Hall JB, et al. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nat Genet. 2022;54(9):1305-19. https://doi.org/10.1038/s41588-022-01148-2
Lombardo MV, Lai MC, Baron-Cohen S. Big data approaches to decomposing heterogeneity across the autism spectrum. Mol Psychiatry. 2019;24(10):1435-50. https://doi.org/10.1038/s41380-018-0321-0
Myers SM, Johnson CP, Lipkin PH, Cartwright JD, Desch LW, Duby JC, et al. Management of children with autism spectrum disorders. Pediatrics. 2007;120(5):1162-82. https://doi.org/10.1542/peds.2007-2362
Posey DJ, Stigler KA, Erickson CA, McDougle CJ. Antipsychotics in the treatment of autism. J Clin Invest. 2008;118(1):6-14. https://doi.org/10.1172/JCI32483
Meza N, Rees R, Escobar Liquitay CM, Franco JVA, Sguassero Y, Williams K, et al. Atypical antipsychotics for autism spectrum disorder: a network meta-analysis. Cochrane Database Syst Rev. 2022;5:CD015114. https://doi.org/10.1002/14651858.CD014965
Shafiq S, Pringsheim T. Using antipsychotics for behavioral problems in children. Expert Opin Pharmacother. 2018;19(13):1475-88. https://doi.org/10.1080/14656566.2018.1509069
Willner K, Vasan S, Patel P, Abdijadid S. Atypical antipsychotic agents. Annu Rep Med Chem. 2024;21(C):1-9. Available from: https://www.ncbi.nlm.nih.gov/books/NBK448156/
Burry L, Mehta S, Perreault MM, Luxenberg JS, Siddiqi N, Hutton B, et al. Antipsychotics for treatment of delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2018;6:CD005594. https://doi.org/10.1002/14651858.cd005594.pub3
Severance EG, Dickerson FB, Yolken RH. Autoimmune phenotypes in schizophrenia reveal novel treatment targets. Pharmacol Ther. 2018;189:184-96. https://doi.org/10.1016/j.pharmthera.2018.05.005
Youngster I, Zachor DA, Gabis LV, Bar-Chaim A, Benveniste-Levkovitz P, Britzi M, et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol. 2014;56(10):990-4. https://doi.org/10.1111/dmcn.12470
Dean L. Risperidone therapy and CYP2D6 genotype. In: Medical genetics summaries. Bethesda: National Center for Biotechnology Information; 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425795/
Panizzutti B, Bortolasci CC, Spolding B, Kidnapillai S, Connor T, Richardson MF, et al. Biological mechanism(s) underpinning the association between antipsychotic drugs and weight gain. J Clin Med. 2021;10(18):1-17. https://doi.org/10.3390/jcm10184095
Hutchinson J, Folawemi O, Bittla P, Kaur S, Sojitra V, Zahra A, et al. The effects of risperidone on cognition in people with autism spectrum disorder: a systematic review. Cureus. 2023;15(9):e43689. https://doi.org/10.7759/cureus.45524
Maneeton N, Maneeton B, Putthisri S, Woottiluk P, Narkpongphun A, Srisurapanont M. Risperidone for children and adolescents with autism spectrum disorder: a systematic review. Neuropsychiatr Dis Treat. 2018;14:1811-20. https://doi.org/10.2147/ndt.s151802
Gettu N, Saadabadi A. Aripiprazole. In: StatPearls. Treasure Island: StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547739/
Tuplin EW, Holahan MR. Aripiprazole, a drug that displays partial agonism and functional selectivity. Curr Neuropharmacol. 2017;15(8):1192-207. https://doi.org/10.2174/1570159X15666170413115754
Urban AE, Cubała WJ. Therapeutic drug monitoring of atypical antipsychotics. Psychiatr Pol. 2017;51(6):1059-77. https://doi.org/10.12740/pp/65307
Hirsch LE, Pringsheim T. Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2016;6:CD009043. https://doi.org/10.1002/14651858.cd009043.pub3
Kurisu K, Yoshiuchi K. Comparison of antipsychotics for the treatment of patients with delirium and QTc interval prolongation: a clinical decision analysis. Front Psychiatry. 2021;12:687414. https://doi.org/10.3389/fpsyt.2021.609678
Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, et al. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology. 2022;47(3):664-72. https://doi.org/10.1038/s41386-021-01163-7
Jiwanmall S, Gopalakrishnan R, Kuruvilla A. Tardive laryngeal dystonia with risperidone – a case report. Indian J Psychiatry. 2021;63(3):306-8. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_340_20
Pondé MP, Freire ACC. Increased anxiety, akathisia, and suicidal thoughts in patients with mood disorder on aripiprazole and lamotrigine. Case Rep Psychiatry. 2015;2015:419746. https://doi.org/10.1155/2015/419746
Prado CM. Farmacogenética em psiquiatria: busca de marcadores de refratariedade em pacientes deprimidos submetidos à ECT [tese]. São Paulo: Universidade de São Paulo; 2018. Available from: http://www.teses.usp.br/teses/disponiveis/5/5142/tde-06062016-113945/
Pondé MP, Freire ACC. Farmacogenômica e doença cardiovascular: onde estamos e para onde vamos. Arq Bras Cardiol. 2020;115(4):690-700. https://doi.org/10.36660/abc.20200151
Kawashima A, Satta Y. Substrate-dependent evolution of cytochrome P450: rapid turnover of the detoxification-type and conservation of the biosynthesis-type. PLoS One. 2014;9(6):e100059. https://doi.org/10.1371/journal.pone.0100059
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103-41. https://doi.org/10.1016/j.pharmthera.2012.12.007
Nahid NA, Johnson JA. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine. Expert Opin Drug Metab Toxicol. 2022;18(11):769-84. https://doi.org/10.1080/17425255.2022.2160317
Henriques TB. Estudo de frequência de polimorfismos em genes envolvidos no risco de efeitos adversos da risperidona em uma amostra da população brasileira [dissertação]. Campinas: Universidade Estadual de Campinas; 2015.
Skadrić I, Stojković O. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population. Int J Legal Med. 2020;134(2):433-9. https://doi.org/10.1007/s00414-019-02234-7
Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol. 2002;53(2):111-22. https://doi.org/10.1046/j.0306-5251.2001.01548.x
Zhou J, Blundell J, Ogawa S, Kwon CH, Zhang W, Sinton C, et al. Pharmacological inhibition of mTORC1 suppresses anatomical, cellular, and behavioral abnormalities in neural-specific Pten knock-out mice. J Neurosci. 2009;29(6):1773-83. https://doi.org/10.1523/JNEUROSCI.5685-08.2009
Laika B, Leucht S, Heres S, Steimer W. Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J. 2009;9(6):395-403. https://doi.org/10.1038/tpj.2009.23
Pratt VM, Cavallari LH, Del Tredici AL, Gaedigk A, Hachad H, Ji Y, et al. Recommendations for clinical CYP2D6 genotyping allele selection: a joint consensus recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group, and the European Society for Pharmacogenomics and Personalized Therapy. J Mol Diagn. 2021;23(9):1047-64. https://doi.org/10.1016/j.jmoldx.2021.05.013
Lopes GS, Lopes JL, Bielinski SJ, Armasu SM, Zhu Y, Cavanaugh DC, et al. Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota. Pharmacogenomics J. 2022;22(2):117-25. https://doi.org/10.1038/s41397-022-00265-9
Scantamburlo G, Tziolia K, Zopf M, Bernardinelli E, Soyal SM, Civello DA, et al. Allele drop out conferred by a frequent CYP2D6 genetic variation for commonly used CYP2D6*3 genotyping assays. Cell Physiol Biochem. 2017;43(6):2297-309. https://doi.org/10.1159/000484380
Kane M. CYP2D6 overview: allele and phenotype frequencies. Bethesda: National Center for Biotechnology Information; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK574601/
Alvarado AT, Ybañez-Julca R, Muñoz AM, Tejada-Bechi C, Cerro R, Quiñones LA, et al. Frequency of CYP2D6*3 and *4 and metabolizer phenotypes in three mestizo Peruvian populations. Pharmacia. 2021;68(4):891-8.
Leitão LPC, Souza TP, Rodrigues JCG, Fernandes MR, Santos S, Santos NPC. The metabolization profile of the CYP2D6 gene in Amerindian populations: a review. Genes (Basel). 2020;11(3):1-12. https://doi.org/10.3390/genes11030262